A patient advocacy group has filed a lawsuit to block the federal government from awarding an exclusive license to Gilead Sciences (GILD) for an experimental cancer therapy, arguing that the potential for a high price may preclude access to many Americans.

At issue is a CAR-T treatment, which relies on the immune system to attack cancer cells. Last December, the National Institutes of Health indicated plans to award a worldwide exclusive license to a CAR-T treatment that is being developed with taxpayer funds to Kite Pharma, which had recently been purchased by Gilead.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy